Neuranics, a trailblazer in healthcare diagnostics, has garnered $700,000 in seed funding, predominantly supported by Inflection Point Ventures (IPV). These resources are earmarked for advancing their technological capabilities and clinical validations, propelling the startup on its journey to transform blood diagnostics.
The startup is crafting an innovative point-of-care blood analyzer that can provide complete blood count (CBC) results within a mere 10 minutes from a simple finger-prick. Tailored for primary and emergency healthcare environments, this device is characterized by its minimal upkeep demands and high efficiency, positioning it as a revolutionary tool in healthcare.
With rapid CBC results generated directly at the care location, while the physician is directly overseeing the patient, treatment and diagnostic decisions can be executed swiftly and accurately without waiting for the traditional sample processing procedures. This results in improved patient outcomes and enhances a clinician’s ability to assess, diagnose, and treat with increased assurance. The broader society benefits from reduced healthcare expenses and heightened quality care. By bypassing unnecessary and potentially costly treatments, such as unsuitable antibiotic prescriptions, and facilitating rapid interventions for critical conditions like sepsis, severe anemia, and thrombocytopenia in dengue cases, this system ensures that care is both timely and effective.
Through its efficient and self-contained haematology design, Neuranics meets a critical need by delivering rapid analysis at the point of care.
Mitesh Shah, IPV’s co-founder, expressed, “Neuranics is addressing the challenge posed by convoluted and time-intensive blood testing through their innovative point-of-care solution, which revolutionizes CBC diagnosis by making the process more accessible and rapid. This enhancement significantly boosts patient care, particularly in exigent scenarios. IPV places its faith in the startup’s cutting-edge technology with hopes for more advancements.”
Dr. Megha Sharma, Neuranics’ Chief Medical Evangelist, states, “Utilizing a straightforward finger-prick capillary blood sample eradicates the necessity for traditional venipuncture, making testing faster, less invasive, and more patient-friendly. This technology furnishes healthcare professionals with instant, actionable insights, even in resource-constrained settings, ultimately ameliorating patient outcomes, notably in primary care centers and during emergency triaging.”
The company has achieved a significant milestone with the granting of a patent, receiving the CDSCO Test License, Ethical Approval from AIIMS Delhi, and progressing through clinical trials.
Praveen Kumar, Neuranics’ Co-founder & CEO, remarks, “We’re re-envisioning diagnostic processes by enabling immediate, precise blood testing that enhances patient-proximity without yielding any quality. Our technology equips healthcare providers with real-time data, redefining care delivery and improving patient outcomes.” Leveraging artificial intelligence on anonymous pathological imaging data developed by the analyzer, Neuranics aspires to establish a contemporary standard for nationwide screening initiatives, thereby uplifting health standards in India and asserting its global leadership in point-of-care blood analysis.”
Neuranics is part of a rapidly growing diagnostics sector, with the global CBC market on course to reach $50 billion, growing at an 8-10% CAGR. The company’s proficiency in precision robotics, machine vision, and microfluidics positions it as a frontrunner in the next generation of diagnostic solutions.